SCHEMBL693529

SCHEMBL693529

CCN(CCCl)Cc1ccccc1Br

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2C19 P33261 2/20 1.00
NFKB1 P19838 1/20 1.00
HSD17B10 Q99714 1/20 1.00
LMNA P02545 2/20 0.97
BLM P54132 1/20 0.97
MAPT P10636 3/20 0.66
TAAR1 Q96RJ0 3/20 0.44
PYCR1 P32322 1/20 0.42
ALDH1A1 P00352 4/20 0.42
BCHE P06276 4/20 0.39
ACHE P22303 4/20 0.39
POLB P06746 2/20 0.39
GPR55 Q9Y2T6 1/20 0.37
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29389684 1.00 TSHR (1.00) TSHRCYP1A2CYP2D6CYP2C19NFKB1
Hydrochloric Acid SCHEMBL2268042 0.98 LMNA (1.00) TSHRCYP1A2CYP2D6CYP2C19NFKB1
Hydrochloric Acid SCHEMBL29390714 0.98 LMNA (1.00) TSHRCYP1A2CYP2D6CYP2C19NFKB1
SCHEMBL4049148 0.85 TSHR (0.81) TSHRCYP1A2CYP2D6CYP2C19NFKB1
SCHEMBL13137718 0.81 MAPT (0.97) TSHRCYP1A2CYP2D6CYP2C19NFKB1
SCHEMBL8483664 0.77 TSHR (0.67) TSHRCYP1A2CYP2D6CYP2C19NFKB1
SCHEMBL22340503 0.76 TSHR (0.67) TSHRCYP1A2CYP2D6CYP2C19NFKB1
Hydrochloric Acid SCHEMBL29455712 0.76 MAPT (0.65) TSHRCYP1A2CYP2D6CYP2C19NFKB1
SCHEMBL8021687 0.74 TSHR (0.59) TSHRCYP1A2CYP2D6CYP2C19NFKB1
Hydrochloric Acid SCHEMBL5108270 0.73 MAPT (0.62) TSHRCYP1A2CYP2D6CYP2C19NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250058091-A1 TREATMENT OF HYPERTENSION BY RENAL VASCULAR DELIVERY OF GUANETHIDINE MERCATOR MEDSYSTEMS, INC. 2025-02-20 US claimed
EP-2768514-A1 LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION Mercator Medsystems, Inc. (US) 2014-08-27 EP claimed
US-20130252932-A1 LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION MERCATOR MEDSYSTEMS, INC. (US) 2013-09-26 US claimed
WO-2013059735-A1 LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION MERCATOR MEDSYSTEMS, INC. (US) 2013-04-25 WO claimed
US-12496469-B2 Devices and methods for endoluminal delivery of either fluid or energy for denervation BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-12-16 US disclosed
US-20250339496-A1 SYSTEMS AND METHODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION TULAVI THERAPEUTICS INC (US) 2025-11-06 US disclosed
EP-3288626-B1 SUBSTANCES AND COMPOSITIONS FOR USE IN BLOCKING NERVE REGENERATION REFLEX MEDICAL INC (US) 2025-10-29 EP disclosed
US-20250288728-A1 SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION TULAVI THERAPEUTICS INC (US) 2025-09-18 US disclosed
US-20250127964-A1 SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION TULAVI THERAPEUTICS INC (US) 2025-04-24 US disclosed
US-20250058091-A1 TREATMENT OF HYPERTENSION BY RENAL VASCULAR DELIVERY OF GUANETHIDINE MERCATOR MEDSYSTEMS, INC. 2025-02-20 US disclosed
EP-3556749-B1 LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION MERCATOR MEDSYSTEMS INC (US) 2023-10-04 EP disclosed
US-11446359-B2 Systems and methods for cardiac plexus neuromodulation Tulavi Therapeutics, Inc. (US) 2022-09-20 US disclosed
EP-0573498-B1 ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS UNIV SASKATCHEWAN (CA) 1998-11-18 EP disclosed
US-5589513-A TREATMENT OF NEURODEGENERATIVE DISEASES; MONOAMINE OXIDASE INHIBITOR AND UPTAKE INHIBITOR CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1996-12-31 US disclosed
US-5508311-A Aliphatic propargylamines as selective MAO-B inhibitors and as neuroprotective agents UNIVERSITY OF SASKATCHEWAN (CA) 1996-04-16 US disclosed
EP-0602044-A4 A CDNA CLONE ENCODING A HUMAN NOREPINEPRHINE TRANSPORTER. OREGON STATE (US) 1994-10-05 EP disclosed
EP-0602044-A1 A cDNA CLONE ENCODING A HUMAN NOREPINEPRHINE TRANSPORTER STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) 1994-06-22 EP disclosed
EP-0573498-A1 ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS UNIVERSITY OF SASKATCHEWAN (CA) 1993-12-15 EP disclosed
WO-1992017568-A1 A cDNA CLONE ENCODING A HUMAN NOREPINEPRHINE TRANSPORTER OREGON HEALTH SCIENCES UNIVERSITY (US) 1992-10-15 WO disclosed
WO-1992015551-A1 ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS UNIVERSITY OF SASKATCHEWAN (CA) 1992-09-17 WO disclosed